These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 9827472)

  • 21. The effects of lipid-lowering and antioxidant vitamin therapies on flow-mediated vasodilation of the brachial artery in older adults with hypercholesterolemia.
    Stein JH; Carlsson CM; Papcke-Benson K; Aeschlimann SE; Bodemer A; Carnes M; McBride PE
    J Am Coll Cardiol; 2001 Dec; 38(7):1806-13. PubMed ID: 11738278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early effects of statin therapy on endothelial function and microvascular reactivity in patients with coronary artery disease.
    Ling MC; Ruddy TD; deKemp RA; Ukkonen H; Duchesne L; Higginson L; Williams KA; McPherson R; Beanlands R
    Am Heart J; 2005 Jun; 149(6):1137. PubMed ID: 15976803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin.
    Guethlin M; Kasel AM; Coppenrath K; Ziegler S; Delius W; Schwaiger M
    Circulation; 1999 Feb; 99(4):475-81. PubMed ID: 9927392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS).
    Nishimura S; Sekiguchi M; Kano T; Ishiwata S; Nagasaki F; Nishide T; Okimoto T; Kutsumi Y; Kuwabara Y; Takatsu F; Nishikawa H; Daida H; Yamaguchi H
    Atherosclerosis; 1999 Jun; 144(2):409-17. PubMed ID: 10407502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium.
    Gould KL; Martucci JP; Goldberg DI; Hess MJ; Edens RP; Latifi R; Dudrick SJ
    Circulation; 1994 Apr; 89(4):1530-8. PubMed ID: 8149518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy.
    Hunninghake DB
    Am J Med; 1998 Feb; 104(2A):9S-13S. PubMed ID: 9550501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease.
    Kroon AA; van Asten WN; Stalenhoef AF
    Ann Intern Med; 1996 Dec; 125(12):945-54. PubMed ID: 8967704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate.
    Seiler C; Suter TM; Hess OM
    J Am Coll Cardiol; 1995 Dec; 26(7):1615-22. PubMed ID: 7594094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LDL cholesterol lowering by bile acid malabsorption during inhibited synthesis and absorption of cholesterol in hypercholesterolemic coronary subjects.
    Gylling H; Miettinen TA
    Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):19-23. PubMed ID: 12125225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physiological basis for angina and ST-segment change PET-verified thresholds of quantitative stress myocardial perfusion and coronary flow reserve.
    Johnson NP; Gould KL
    JACC Cardiovasc Imaging; 2011 Sep; 4(9):990-8. PubMed ID: 21920337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis.
    Kroon AA; Aengevaeren WR; van der Werf T; Uijen GJ; Reiber JH; Bruschke AV; Stalenhoef AF
    Circulation; 1996 May; 93(10):1826-35. PubMed ID: 8635262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement of coronary vasodilatation capacity through single LDL apheresis.
    Mellwig KP; Baller D; Gleichmann U; Moll D; Betker S; Weise R; Notohamiprodjo G
    Atherosclerosis; 1998 Jul; 139(1):173-8. PubMed ID: 9699905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease.
    Eichstädt HW; Eskötter H; Hoffman I; Amthauer HW; Weidinger G
    Am J Cardiol; 1995 Jul; 76(2):122A-125A. PubMed ID: 7604786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between hypercholesterolemia, lipid-lowering therapy and coronary flow velocity reserve evaluated by stress transesophageal echocardiography in patients with a negative coronary angiogram.
    Nemes A; Neu K; Forster T; Gruber N; Csanády M
    Echocardiography; 2004 Jan; 21(1):37-41. PubMed ID: 14717719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: a mechanism for reducing clinical events?
    Cohen JD; Drury JH; Ostdiek J; Finn J; Babu BR; Flaker G; Belew K; Donohue T; Labovitz A
    Am Heart J; 2000 Apr; 139(4):734-8. PubMed ID: 10740160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Short- and long-term effects of intensified versus conventional antilipidemic therapy in patients with coronary heart disease. Results from the Lipid-Coronary Artery Disease (L-CAD) Study].
    Arntz HR; Wunderlich W; Schnitzer L; Stern R; Fischer F; Agrawal R; Linderer T; Schultheiss HP
    Z Kardiol; 1999 Aug; 88(8):582-90. PubMed ID: 10506395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early detection of abnormal coronary flow reserve in asymptomatic men at high risk for coronary artery disease using positron emission tomography.
    Dayanikli F; Grambow D; Muzik O; Mosca L; Rubenfire M; Schwaiger M
    Circulation; 1994 Aug; 90(2):808-17. PubMed ID: 8044952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simvastatin compared to fluvastatin in the reduction of serum lipids and apolipoproteins in patients with ischaemic heart disease and moderate hypercholesterolaemia.
    Sigurdsson G; Haraldsdottir SO; Melberg TH; Tikkanen MJ; Miettinen TE; Kristianson KJ
    Acta Cardiol; 1998; 53(1):7-14. PubMed ID: 9638964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beneficial effect of simvastatin treatment on LDL oxidation and antioxidant protection is more pronounced in combined hyperlipidemia than in hypercholesterolemia.
    Molcányiová A; Stancáková A; Javorský M; Tkác I
    Pharmacol Res; 2006 Sep; 54(3):203-7. PubMed ID: 16737822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aggressive lipid therapy in the statin era.
    Farmer JA
    Prog Cardiovasc Dis; 1998; 41(2):71-94. PubMed ID: 9790411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.